Abstract: Cyclic-GMP-AMP synthase (cGAS) and cyclic-GMP-AMP (cGAMP), including 2?3-cGAMP, 2?2-cGAMP, 3?2?-cGAMP and 3?3?-GAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies, and diagnostics.
Type:
Grant
Filed:
May 7, 2019
Date of Patent:
December 17, 2019
Assignee:
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Abstract: Disclosed herein are Click Nucleic Acid Polymers (CNA-polymers) that comprise repeating dimer, trimer and tetramer units. The disclosed polymers can be used for antisense applications, for example, in treatment of “trinucleotide repeat disorders, i.e., Huntington's Disease and the like.
Type:
Grant
Filed:
October 6, 2017
Date of Patent:
December 17, 2019
Assignee:
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY
Inventors:
Christopher N. Bowman, Weixian Xi, Sankha Pattanayak
Abstract: The disclosure relates to sexually transmitted disease ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Abstract: The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAG3, CD137(4-1BB) and a non-coding immunomodulating DNA.
Type:
Grant
Filed:
September 9, 2016
Date of Patent:
November 26, 2019
Assignee:
Mologen AG
Inventors:
Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Alfredo Zurlo
Abstract: Provided herein are branched oligonucleotides exhibiting efficient and specific tissue distribution, cellular uptake, minimum immune response and off-target effects, without formulation.
Type:
Grant
Filed:
January 30, 2017
Date of Patent:
November 19, 2019
Assignee:
UNIVERSITY OF MASSACHUSETTS
Inventors:
Anastasia Khvorova, Matthew Hassler, Julia Alterman, Bruno Miguel da Cruz Godinho
Abstract: The invention relates to RNAi agents, e.g. double-stranded RNAi agents, targeting the HAO1 gene, and method of using such RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1. Described herein are double-stranded RNAi agents which inhibit the expression of a HA01 gene in a cell, such as a cell within a subject, e.g., a mammal, such as a human having a HAO1 associated disorder, and uses of such double-stranded RNAi agents. In certain aspects of the invention, substantially all of the nucleotides of an iRNA of the invention are modified.
Type:
Grant
Filed:
October 9, 2015
Date of Patent:
November 19, 2019
Assignee:
Alnylam Pharmaceuticals, Inc.
Inventors:
William Querbes, Kevin Fitzgerald, Brian Bettencourt, Abigail Liebow, David V. Erbe
Abstract: The present invention provides a method for detecting interactions between or with any two of at least three target substrates, or any two of at least three features of a target substrate, or a combination of interactions and features of target substrates, by a multiplexed proximity ligation assay, said method comprising: a) for each of the at least three target substrates or features, providing a proximity probe comprising a binding moiety with affinity for the feature or binding site on said substrate, and a proximity probe oligonucleotide coupled on the binding moiety; wherein each of the proximity probe oligonucleotide carries a unique tag sequence; b) mixing the proximity probes with a sample, under a condition to allow binding of each proximity probe to its respective binding site or feature on each of said substrates through the binding moiety, c) simultaneous with, or following step b), forming circularized DNA molecules where any two proximity probes bind sufficiently close to each other on the subst
Type:
Grant
Filed:
May 23, 2012
Date of Patent:
November 5, 2019
Assignee:
NAVINCI DIAGNOSTICS AB
Inventors:
Mats Gullberg, Ola Söderberg, Ulf Landegren, Yanling Liu
Abstract: The invention relates to novel miRNA markers useful for diagnosis or therapy of disease, in particular for neuronal disorders such as Alzheimer's Disease (AD).
Type:
Grant
Filed:
November 4, 2013
Date of Patent:
October 29, 2019
Assignee:
Siemens Aktiengesellschaft
Inventors:
Andreas Keller, Cord Friedrich Stähler, Christina Backes, Eckart Meese, Petra Leidinger, Andreas Kappel
Abstract: Described are compounds and methods useful for the treatment and investigation of diseases and disorders associated with expanded repeat-containing RNA molecules. In certain embodiments, compounds and methods useful for the modulation of ATXN-3 pre-mRNA are described. In certain embodiments, compounds and methods useful for the modulation of ATN-1 mRNA are described.
Type:
Grant
Filed:
July 31, 2014
Date of Patent:
October 8, 2019
Assignees:
IONIS PHARMACEUTICALS, INC., THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
Thazha P. Prakash, Jiaxin Hu, Jing Liu, Dongbo Yu, David Corey, Eric E. Swayze
Abstract: The present invention is intended to provide a novel fluorescent labeled single-stranded nucleic acid, by which the background of an exciton oligomer can be further reduced and the novel use thereof. The present invention relates to a labeled single-stranded nucleic acid having at least two fluorescent atomic group pairs that exhibit an exciton effect. The labeled single-stranded nucleic acid is characterized in that the emission peak wavelength of one of the fluorescent atomic group pairs (fluorescent atomic group pair A) is shorter than the excitation peak wavelength of the other fluorescent atomic group pair (fluorescent atomic group pair B), and the fluorescent atomic group pairs A and B have a Förster resonance energy transfer (FRET) effect. This fluorescent labeled single-stranded nucleic acid is usable as a primer for amplifying a target nucleic acid or a probe to be hybridized with a target nucleic acid.
Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
Type:
Grant
Filed:
July 11, 2018
Date of Patent:
September 24, 2019
Assignees:
The Regents of the University of California, University of Vienna
Inventors:
Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
Type:
Grant
Filed:
July 11, 2018
Date of Patent:
September 17, 2019
Assignees:
The Regents of the University of California, University of Vienna
Inventors:
Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
Abstract: The present disclosure provides variant Cas9 proteins, nucleic acids encoding the variant Cas9 proteins, and host cells comprising the nucleic acids. The present disclosure provides systems that include a subject variant Cas9 protein (and/or a nucleic acid encoding the variant Cas9 protein) and a Cas9 guide RNA. In some cases, a subject system includes a PAMmer and/or a donor polynucleotide. The variant Cas9 proteins and the nucleic acids encoding the variant Cas9 proteins are useful in a wide variety of methods, which are also provided. In some embodiments, a variant Cas9 protein includes a RuvC domain, an HNH domain, and a disrupted RuvC/HNH linker region that reduces the RuvC cleavage activity of the protein. In some embodiments, a variant Cas9 protein includes a deletion (of all or a part of the HNH domain) or an insertion (within the HNH domain) that reduces the HNH cleavage activity of the protein.
Type:
Grant
Filed:
June 1, 2016
Date of Patent:
August 27, 2019
Assignee:
the regents of the university of california
Inventors:
Samuel H. Sternberg, Jennifer A. Doudna
Abstract: The invention relates to an oligonucleotide including one or more modified nucleoside bases having the structure -B-L-A wherein for each of the modified nucleosides A is independently a monosaccharide or oligosaccharide, L is a linker molecule, and B is independently a pyrimidine or pyridine base linked to the sugar-phosphate backbone of the oligonucleotide; and wherein the oligonucleotide binds specifically to a carbohydrate-binding monoclonal antibody with an affinity of less than 100 nM. Immunogenic conjugates that include the oligonucleotide, and pharmaceutical compositions that include the oligonucleotide or the immunogenic conjugate are also disclosed. Various method of using the oligonucleotides, immunogenic conjugates, and pharmaceutical compositions are disclosed, including inducing an immune response, inhibiting viral or bacterial infection, treating a cancerous condition, and detecting a neutralizing antibody.
Abstract: Described herein are novel divalent nucleobases that each bind two nucleic acid strands, matched or mismatched when incorporated into a nucleic acid or nucleic acid analog backbone (a genetic recognition reagent, or genetic recognition reagent). In one embodiment, the genetic recognition reagent is a peptide nucleic acid (PNA) or gamma PNA (?PNA) oligomer. Uses of the divalent nucleobases and monomers and genetic recognition reagents containing the divalent nucleobases also are provided.
Type:
Grant
Filed:
April 11, 2014
Date of Patent:
August 6, 2019
Assignee:
Carnegie Mellon University
Inventors:
Danith H. Ly, Suresh Kumar Gopalsamy, Arunava Manna
Abstract: The invention described in the application relates to a long non-coding RNA expressed in cancer. The invention thus provides methods and compositions for evaluating levels of the long non-coding RNA to assess the aggressiveness of a cancer and for modulating levels of the long non-coding RNA.
Type:
Grant
Filed:
November 16, 2016
Date of Patent:
July 30, 2019
Assignee:
The Regents of the University of California
Inventors:
Terumi Kohwi-Shigematsu, Yoshinori Kohwi, Ellen C. Ordinario, Michael A. Balamotis, Hye-Jung Han
Abstract: Oligonucleotides with a novel sugar-phosphate backbone containing at least one 2?-arabino-fluoronucleoside and an internucleoside 3?-NH—P(—O)(OR)—O-5? linkage, where R is a positively charged counter ion or hydrogen, and methods of synthesizing and using the inventive oligonucleotides are provided. The inventive phosphoramidate 2?-arabino-fluorooligonucleotides have a high RNA binding affinity to complementary nucleic acids and are base and acid stable.
Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
Type:
Grant
Filed:
November 27, 2018
Date of Patent:
July 23, 2019
Assignees:
The Regents of the University of California, University of Vienna, Emmanuelle Charpentier
Inventors:
Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
Abstract: Embodiments are directed to methods for joining oligonucleotides. The methods include joining together one or more oligonucleotides by reacting an alkyne group linked to an oligonucleotide with an azide group linked to an oligonucleotide to form a triazole linkage. The alkyne group is a strained alkyne group. The methods can include ligating together ends of one or more oligonucleotides or cross-linking strands of an oligonucleotide duplex to form the triazole linkage. The methods described allow oligonucleotide strands to be ligated together without the need for a ligase enzyme. The methods can be useful for joining together single strands of DNA, cross-linking complementary strands, cyclizing single and double strands, labeling oligonucleotides with reporter groups, attaching DNA to surfaces, producing analogs of DNA with modified nucleobases and backbones, synthesizing large chemically modified RNA constructs, and creating biochemically active PCR templates.
Abstract: The present invention encompasses a class of compounds known as splice modulating oligonucleotides (SMOs) that modulate pre-mRNA splicing, thereby affecting expression and functionality of a specific protein in a cell. The present invention further provides compositions and methods for modulating pre-mRNA splicing using a SMO of the invention to abrogate disease-causing mutations in a protein. Accordingly, the present invention provides compositions and methods of treating a subject at risk of, susceptible to, or having a disease, disorder, or condition associated with aberrant or unwanted target pre-mRNA expression or activity.
Type:
Grant
Filed:
July 30, 2018
Date of Patent:
July 2, 2019
Assignee:
Drexel University
Inventors:
Gordon J. Lutz, Melanie K. Tallent, Nicole Michele Lykens
Abstract: Cyclic-GMP-AMP synthase (cGAS) and cyclic-GMP-AMP (cGAMP), including 2?3-cGAMP, 2?2-cGAMP, 3?2?-cGAMP and 3?3?-GAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies and diagnostics.
Type:
Grant
Filed:
December 16, 2013
Date of Patent:
July 2, 2019
Assignee:
Board of Regents, The University of Texas System
Abstract: Chimeric protein constructs including a herpesvirus glycoprotein D (gD) and a heterologous polypeptide that interact with herpes virus entry mediator (HVEM) and enhance and enhance an immune response against the heterologous polypeptide and methods for their use are provided.
Type:
Grant
Filed:
June 30, 2017
Date of Patent:
June 25, 2019
Assignee:
THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
Inventors:
Hildegund C. J. Ertl, Marcio O. Lasaro, Luis C. S. Ferreira
Abstract: Described herein are methods of syntheses of phosphorous atom-modified nucleic acids comprising chiral X-phosphonate moieties. The methods described herein provide backbone-modified nucleic acids in high diasteteomeric purity via an asymmetric reaction of an achiral molecule comprising a chemically stable H-phophonate moiety with a nucleoside/nucleotide.
Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
Type:
Grant
Filed:
July 11, 2018
Date of Patent:
June 4, 2019
Assignees:
The Regents of the University of California, University of Vienna, Emmanuelle Charpentier
Inventors:
Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
Abstract: The present invention features Nicotiana nucleic acid sequences such as sequences encoding constitutive, or ethylene or senescence induced polypeptides, in particular cytochrome p450 enzymes, in Nicotiana plants and methods for using these nucleic acid sequences and plants to alter desirable traits, for example by using breeding protocols.
Type:
Grant
Filed:
February 20, 2014
Date of Patent:
May 21, 2019
Assignee:
U.S. Smokeless Tobacco Company LLC
Inventors:
Dongmei Xu, Mark T. Nielsen, Yanxin Shen
Abstract: The present invention relates to a nucleic acid linker for producing a complex of mRNA, and a protein or a peptide which is encoded by the mRNA, the linker comprising: a spacer portion at the 5?-terminal; a polynucleotide portion hybridizable with at least a part of a sequence of the mRNA; and an arm portion which has a connection portion for the protein or the peptide at the 3?-terminal, in which the spacer portion, the polynucleotide portion, and the arm portion form a single strand, and in which the polynucleotide portion contains a photoreactive base derivative.
Type:
Grant
Filed:
September 10, 2015
Date of Patent:
May 21, 2019
Assignees:
THE UNIVERSITY OF TOKYO, NIKON CORPORATION
Abstract: The present invention relates to a method for screening an inhibitor of ATP11C or CDC50A, comprising determining (a) exposure of phosphatidylserine on cell surface, (b) engulfment of cells by macrophages, or (c) cleavage of ATP11C by caspase. The present invention also relates to a method for inducing engulfment of cells by macrophages, comprising inhibiting ATP11C or CDC50A.
Abstract: A method of altering a eukaryotic cell is provided including transfecting the eukaryotic cell with a nucleic acid encoding RNA complementary to genomic DNA of the eukaryotic cell, transfecting the eukaryotic cell with a nucleic acid encoding an enzyme that interacts with the RNA and cleaves the genomic DNA in a site specific manner, wherein the cell expresses the RNA and the enzyme, the RNA binds to complementary genomic DNA and the enzyme cleaves the genomic DNA in a site specific manner.
Type:
Grant
Filed:
July 2, 2015
Date of Patent:
April 30, 2019
Assignee:
President and Fellows of Harvard College
Inventors:
George M. Church, Prashant G. Mali, Luhan Yang
Abstract: Embodiments of the present disclosure relate generally to reporter compositions which are synthetic nucleotides that comprise nucleotides with a high charge mass moiety attached thereto via a linker molecule. The linker molecules can vary in length in part to enable the high charge mass moiety to extend out from a DNA polymerase complex so that polymerization may not be influenced.
Type:
Grant
Filed:
January 3, 2017
Date of Patent:
April 30, 2019
Assignee:
QUANTUMDX GROUP LIMITED
Inventors:
Jonathan J. O'Halloran, Joseph H. Hedley
Abstract: Provided herein are therapeutic agents having specificity for human CLPTM1 L polypeptide, including therapeutic agents comprising one or more CLPTM1 L-targeting agents, compositions comprising such therapeutic agents, and methods of using such compositions for treating or preventing a cancer, pre-cancerous lesion, or other disease condition associated with CLPTM1 L protein dysfunction (e.g., pathogenic production, modification, or function).
Abstract: The present invention provides, among other things, multimeric coding nucleic acids that exhibit superior stability for in vivo and in vitro use. In some embodiments, a multimeric coding nucleic acid (MCNA) comprises two or more encoding polynucleotides linked via 3? ends such that the multimeric coding nucleic acid compound comprises two or more 5? ends.
Type:
Grant
Filed:
April 7, 2017
Date of Patent:
April 23, 2019
Assignee:
Translate Bio, Inc.
Inventors:
Frank DeRosa, Michael Heartlein, Daniel Crawford, Shrirang Karve
Abstract: The present invention relates to a method of producing a non-human, mammalian oocyte carrying a modified target sequence in its genome, the method comprising the steps of introducing into a non-human, mammalian oocyte: (a) a clustered, regularly interspaced, short palindromic repeats (CRISPR)-associated protein 9 (Cas9 protein) or a nucleic acid molecule encoding said Cas9 protein; and (b-i) a target sequence specific CRISPR RNA (crRNA) and a trans-activating crRNA (tracr RNA) or a nucleic acid molecule encoding said RNAs; or (b-ii) a chimaeric RNA sequence comprising a target sequence specific crRNA and tracrRNA or a nucleic acid molecule encoding said RNA; wherein the Cas9 protein introduced in (a) and the RNA sequence(s) introduced in (b-i) or (b-ii) form a protein/RNA complex that specifically binds to the target sequence and introduces a single or double strand break within the target sequence.
Type:
Grant
Filed:
July 13, 2016
Date of Patent:
February 26, 2019
Assignee:
HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT
Inventors:
Ralf Kühn, Wolfgang Wurst, Oskar Ortiz Sanchez
Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3?-substituted methyl or alkynyl nucleosides of Formula I: (I); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, PD, RA, RB1, RB2, RC and Z are as defined herein.
Type:
Grant
Filed:
April 16, 2015
Date of Patent:
February 12, 2019
Assignee:
IDENIX PHARMACEUTICALS LLC
Inventors:
David Dukhan, Cyril B. Dousson, Gilles Gosselin, Jean-Laurent Paparin, Guillaume Brandt, Rachid Rahali, Aurelien Salanson, François-René Alexandre
Abstract: Aspects of the present disclosure include compositions that make use of phosphorus and/or nucleobase protecting groups which find use in the synthesis of long polynucleotides. Phosphorus protecting groups are provided that help increase the stepwise coupling yield and/or phosphorous protecting groups that can be removed during the oxidation step. Amidine nucleobase protecting groups are provided that find use in the subject compositions and methods which provides for e.g., increased resistance to depurination during polynucleotide synthesis. In some instances, the methods and compositions disclosed herein utilize a combination of the phosphorus and amidine nucleobase protecting groups in the synthesis of polynucleotides having a sequence of 200 or more monomeric units in length. Also provided are methods for synthesizing a polynucleotide (e.g., a DNA) using one or more compounds disclosed herein.
Type:
Grant
Filed:
April 30, 2015
Date of Patent:
February 5, 2019
Assignee:
Agilent Technologies, Inc.
Inventors:
Douglas J. Dellinger, Luca Monfregola, Marvin Caruthers, Mithun Roy
Abstract: The invention uses polypeptide antigens and/or OMVs to immunize against serogroups A, C, W135 and Y (and against serogroup Y in particular). Serogroup B polypeptides can achieve this protection, thus permitting a single polypeptide-based vaccine to be used for protecting against all of serogroups A, B, C, W135 and Y.
Type:
Grant
Filed:
April 22, 2005
Date of Patent:
February 5, 2019
Assignee:
GLAXOSMITHKLINE BIOLOGICALS S.A.
Inventors:
Mario Contorni, Marzia Giuliani, Mariagrazia Pizza
Abstract: The present invention discloses Hemipteran insect inhibitory proteins, methods of using such proteins, nucleotide sequences encoding such proteins, methods of detecting and isolating such proteins, and their use in agricultural systems.
Type:
Grant
Filed:
July 17, 2017
Date of Patent:
January 29, 2019
Assignee:
Monsanto Technology LLC
Inventors:
James A. Baum, Artem G. Evdokimov, Farhad Moshiri, Timothy J. Rydel, Eric J. Sturman, Moritz von Rechenberg, Halong Vu, Andrew M. Wollacott, Meiying Zheng
Abstract: Various aspects provided herein relate to compositions and methods for altering the content of polyunsaturated fatty acids in animals, e.g., non-human animals. Transgenic animals (e.g., non-human animals) that are capable of converting carbohydrates and/or saturated fats to polyunsaturated fatty acids (e.g., n-6 and/or n-3 fatty acids) and uses thereof are also provided herein.
Abstract: The present invention relates to an improved RNA transcription vector, which is very suitable for the production of mRNA for in vivo therapeutic purposes. The improvements in the vector reside in the presence of a translation enhancer (TE) and a nuclear retention element (NRS), especially when the latter is the “Expression and Nuclear Retention Element” (ENE) of Kaposi's sarcoma associated Herpes virus (KSHV).
Abstract: Provided is a novel useful microRNA having improved anti-tumor activity, obtained by introducing a variation in a microRNA which is present in-vivo and which exhibits an anti-tumor effect. This microRNA containing a base sequence (SEQ ID NO: 1) obtained by varying a predetermined region of the base sequence of miR-29b is able to exhibit a particularly outstanding anti-tumor effect.
Abstract: The present disclosure relates to photoactivable protecting groups containing a diarylsulfide chromophore, a method for the synthesis thereof and their use as photoactivable protecting groups using maskless photolithography based array synthesis.
Abstract: The invention provides methods, compositions, kits and devices for the detection of target molecules. In some embodiments, the invention allows for multiplexed target molecule detection.
Abstract: Described are methods for production of RNA transcripts using a non-amplified, linearized DNA template in an in vitro transcription reaction. Enzymatic 5? capping and oligo dT purification can also be included in the methods.
Type:
Grant
Filed:
March 13, 2014
Date of Patent:
November 27, 2018
Assignee:
ModernaTX, Inc.
Inventors:
Stephane Bancel, William Joseph Issa, John Grant Aunins, Tirtha Chakraborty
Abstract: The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a pattern of deoxyribonucleotides (in most embodiments, the pattern comprises at least one deoxyribonucleotide-deoxyribonucleotide base pair) designed to direct the site of Dicer enzyme cleavage within the dsNA molecule. Deoxyribonucleotides of the dsNA molecules of the invention are located within a region of the dsNA that can be excised via Dicer cleavage to generate an active siRNA agent that no longer contains the deoxyribonucleotide pattern (e.g., deoxyribonucleotide-deoxyribonucleotide base pairs). Such DNA-extended Dicer-substrate siRNAs (DsiRNAs) were demonstrated to be more effective RNA inhibitory agents than corresponding double stranded RNA-extended DsiRNAs.
Abstract: Described are post transcriptionally chemically modified double strand RNAs (MdsRNAs) having more than 30 base pairs. The MdsRNAs inhibit gene expression in target organisms. Also described are methods of making and using MdsRNAs.
Type:
Grant
Filed:
November 6, 2017
Date of Patent:
November 20, 2018
Assignee:
nanoSUR LLC
Inventors:
Juan P. Arhancet, Sreevishnu Cheerla, Graciela B. Arhancet, David B. Rozema
Abstract: Described herein are oligosaccharide-oligonucleotide conjugates useful as vaccines against one or more human or veterinary therapeutic indications, and methods of synthesizing and identifying them. The conjugates may be identified using non-human antibodies as binding targets, thereby expanding the power and scope of the invention. Efficacious conjugates may be identified through an iterative screening process.
Type:
Grant
Filed:
June 19, 2015
Date of Patent:
November 13, 2018
Assignee:
Brandeis University
Inventors:
Isaac J. Krauss, Lizbeth K. Hedstrom, Iain S. MacPherson
Abstract: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose that further includes a tether having one or more linking groups, in which at least one of the linking groups is a cleavable linking group. The tether in turn can be connected to a selected moiety, e.g., a ligand, e.g., a targeting or delivery moiety, or a moiety which alters a physical property. The cleavable linking group is one which is sufficiently stable outside the cell such that it allows targeting of a therapeutically beneficial amount of an iRNA agent (e.g., a single stranded or double stranded iRNA agent), coupled by way of the cleavable linking group to a targeting agent—to targets cells, but which upon entry into a target cell is cleaved to release the iRNA agent from the targeting agent.
Type:
Grant
Filed:
September 9, 2016
Date of Patent:
November 6, 2018
Assignee:
Alnylam Pharmaceuticals, Inc.
Inventors:
Muthiah Manoharan, Kallanthottathil G. Rajeev
Abstract: Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.
Type:
Grant
Filed:
September 18, 2015
Date of Patent:
October 30, 2018
Assignee:
Araxes Pharma LLC
Inventors:
Matthew Robert Janes, Matthew Peter Patricelli, Liansheng Li, Pingda Ren, Yi Liu
Abstract: The disclosure relates to immunogenic and vaccine compositions comprising Streptococcus exotoxins and/or bacterial thermolysins from M4 protease family. Also provided are kits, methods and uses of said compositions for treating or preventing laminitis in a hooved animal.
Abstract: The present invention relates to ?-PNA monomers according to Formula I where substituent groups R1, R2, R3, R4, R5, R6, B and P are defined as set forth in the specification. The invention also provides methodology for synthesizing compounds according to Formula I and methodology for synthesizing PNA oligomers that incorporate one or more Formula I monomers.
Type:
Grant
Filed:
October 23, 2015
Date of Patent:
October 9, 2018
Assignee:
CARNEGIE MELLON UNIVERSITY
Inventors:
Danith H. Ly, Srinivas Rapireddy, Bichismita Sahu
Abstract: The present invention relates to new triphosphate-modified oligonucleotides which may act as RIG-I ligands as well as a new method allowing the synthesis and purification in high yield and purity suitable for pharmaceutical applications.